A
Alcista
Alcista · 25%SPRY
$57.15
Precio del escenario
$4.290
+0.061 (+1.42%)Al cierre
Loading chart…
- Máximo
- 4.440
- Apertura
- 4.250
- Precio medio ponderado por volumen
- 4.32
- Volumen
- 1.54M
- Capitalización
- 780.01M
- Mínimo
- 4.225
- Importe
- 6.66M
- EV/EBITDA, TTM
- -1.75
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Análisis de IA of ARS Pharmaceuticals Inc (SPRY)
MantenerARS Pharmaceuticals Inc is not a good buy right now due to its current price of $4.02 being significantly lower than the analyst price targets of $15 and $30, indicating potential upside. However, the stock has a low RSI of 39.167, suggesting it may be oversold, but the recent 65.01% year-to-date decline raises concerns about its stability.
Métricas de valoración
El PER previsto actual de ARS Pharmaceuticals Inc (SPRY) es 0.00, frente a su media de 5 años de -11.44.
Escenarios de precio de Alphio AI para SPRY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SPRY en cartera
Cronología de eventos
Noticias
7.010-02PRnewswireARS Pharmaceuticals Class Action Reminder
7.009-30PRnewswireARS Pharmaceuticals Faces Class Action Over CVS Caremark Coverage Delay
7.009-29PRnewswireARS Pharmaceuticals Class Action Reminder
7.009-24PRnewswireFaruqi & Faruqi Encourages ARS Investors to Reach Out
7.009-21PRnewswireARS Pharmaceuticals Class Action Notice Issued
Preguntas frecuentes sobre SPRY, respondidas por Alphio AI
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
ARS Pharmaceuticals Inc is not a good buy right now due to its current price of $4.02 being significantly lower than the analyst price targets of $15 and $30, indicating potential upside. However, the stock has a low RSI of 39.167, suggesting it may be oversold, but the recent 65.01% year-to-date decline raises concerns about its stability.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.